Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01102972 · ClinicalTrials.gov registry record · Phase 4
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
A Phase 4 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 297
- Enrollment target
NCT01102972 is a Phase 4 study that has completed, run by ViiV Healthcare. The registered enrollment target is 297 participants.
The verdict
NCT01102972, a Phase 4 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 297 participants
- Enrollment target
Study Summary
This study is designed to compare the efficacy and safety of simplifying therapy from a regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine (TDF/FTC) to a regimen of ATV + abacavir sulfate/lamivudine (ABC/3TC) without RTV in virologically suppressed, HIV-1 infected, HLA-B\*5701 negative subjects for 48 weeks.
Interventions
- DRUG Reyataz + Norvir + Truvada
- DRUG Reyataz + Epzicom
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01102972
The ClinicalTrials.gov registry entry for NCT01102972 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Reyataz + Norvir + Truvada is the first listed.
NCT01102972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01102972 about?
NCT01102972 is a clinical study titled "A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)". This study is designed to compare the efficacy and safety of simplifying therapy from a regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine (TDF/FTC) to a regimen of ATV + abacavir sulfate/lamivudine (ABC/3TC) without RTV in virologically suppressed, HIV-1 infected, HLA-B\*5701 n...
What is the current status of trial NCT01102972?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 297 participants. The study started on 2010-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01102972?
The interventions under investigation include: Reyataz + Norvir + Truvada (DRUG), Reyataz + Epzicom (DRUG).
Who is sponsoring clinical trial NCT01102972?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.